04428nam 2201117z- 450 991061946550332120231214133656.03-0365-5222-7(CKB)5670000000391619(oapen)https://directory.doabooks.org/handle/20.500.12854/93214(EXLCZ)99567000000039161920202210d2022 |y 0engurmn|---annantxtrdacontentcrdamediacrrdacarrierNovel Anti-cancer Agents and Cellular Targets and Their Mechanism(s) of ActionMDPI - Multidisciplinary Digital Publishing Institute20221 electronic resource (206 p.)3-0365-5221-9 Patient outcomes remain poor for many cancers despite improvements in treatments and new molecular-targeted biomedicines for certain cancer types or subtypes. Dose-limiting toxicity, a narrow therapeutic index, and the development of resistance to traditional anti-cancer agents are well-established. It is apparent that inherent and acquired drug resistance are major challenges with molecular-targeted agents and that on- as well as off-target side effects can still occur. Other issues include drug metabolism by the body and safely supplying a sufficient amount of active drug to the tumor cells. There is a clear and urgent need for new molecular targets and drugs that specifically target cancer cells in different ways to existing approved drugs. This book, through a collection of eight research articles and two review articles from the Biomedicines themed Special Issue ‘Novel Anti-Cancer Agents and Cellular Targets and Their Mechanism(s) of Action’, provides a snapshot of some of the diverse and exciting research approaches being taken by the cancer research community in trying to address some of these therapeutic challenges.Novel Anti-cancer Agents and Cellular Targets and Their MechanismTechnology: general issuesbicsscHistory of engineering & technologybicsscmicrotubule acetylationtriple-negative breast canceranti-cancer agentapoptosisK5628-hydroxydaidzeinautophagyBCR-ABLMAPKNF-κBc-mycRNA interferencesiRNAoncogenegene silencingexpressionnanosystemsCytochrome P450CYP1A1CYP1B1CYP2W1breast cancerprodrugbioprecursorduocarmycinphortressAQ4N5-FU resistancecolorectal cancerdrug repurposingGenomics of Drug Sensitivity in CancerConnectivity Mapanticancer drugB-lactam steroid alkylatorssynthetic lethalitypoly (ADP-ribose) polymerase inhibitorsovarian cancerhybrid steroidal alkylating agentsmigrationinvasionglioblastomaCCN1mesenchymal-amoeboid transitionbiomarkerHepG2Huh7isatin sulfonamidesangiogenesiscancer hallmarksmolecular dockingEGFR tyrosine kinase inhibitorphoton upconversiontriplet-triplet annihilationin vivo imagingPLGAnanoparticlesaffibody moleculehuman epidermal growth factor receptor 3 (HER3)BxPC-3emtansineDM1albumin binding domainaffibody drug conjugate (AffiDC)Technology: general issuesHistory of engineering & technologyAllison Simon Jedt1329056Allison Simon JothBOOK9910619465503321Novel Anti-cancer Agents and Cellular Targets and Their Mechanism(s) of Action3039279UNINA